Ferring Pharmaceuticals has announced the launch of Nocdurna (desmopressin acetate) in the United States, marking a significant advancement in the treatment of nocturia caused by nocturnal polyuria. This new medication is designed for adults who experience the disruptive need to urinate at least twice during the night. Nocdurna will be available by prescription in pharmacies […]
The US Food and Drug Administration has approved Noctiva (desmopressin acetate) developed by Serenity Pharmaceuticals for the treatment of nocturia syndrome in adults.
Serenity Pharmaceuticals has received U.S. Food and Drug Administration (FDA) approval for Noctiva (desmopressin acetate), a nasal spray developed to treat nocturnal polyuria syndrome in adults. This marks a significant milestone as Noctiva becomes the first FDA-approved treatment specifically for nocturnal urine overproduction, commonly known as nocturia syndrome. Groundbreaking Treatment for Nocturnal Polyuria Nocturnal polyuria […]